另一种翻译PPARG的异形表明AF-1域抑制作为胰岛素敏感性标
Xiaomi Du1,2, Karen Mendez-Lara1, Siqi Hu1
1Division of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA.
Diabetes
|January 24, 2025
概括
基因选显示,氧体增殖器激活受体玛 (PPARG) 基因的突变,特别是影响AF-1域的突变,增强了它的活性. 这一发现表明PPARG变异可能会降低代谢综合征的严重程度,并为胰岛素敏感性提供治疗潜力.
科学领域:
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 过氧体增殖器激活受体玛 (PPARG) 基因在代谢调节中起着至关重要的作用.
- 替代翻译起点可以产生具有独特功能性质的蛋白质异型.
- PPARγ的N端激活函数1 (AF-1) 域对其转录活性至关重要.
研究的目的:
- 调查PPARG编码序列中遗传突变的功能后果.
- 描述缺少AF-1域的截断PPARγ M135异型的作用.
- 探索PPARG变体,代谢综合征和胰岛素敏感性之间的联系.
主要方法:
- 对PPARG基因进行全面的遗传查.
- 从另一个转化起点点生成的截断PPARγ异型 (M135) 的分析.
- 评估PPARγ活性及其与人类罕见变异载体代谢综合征严重程度的关联.
主要成果:
- 跨PPARG的破坏性突变会影响其功能.
- 缺少AF-1域的PPARγ M135异型体,表现出激素激剂诱导的交换活化增加.
- 在人类中破坏AF-1域的遗传变异增强了PPARγ活性,并降低了代谢综合征的严重程度.
结论:
- PPARγ的AF-1域是其活性和代谢功能的关键调节者.
- 针对AF-1域是一个有前途的治疗策略,可以提高胰岛素敏感度.
- 了解PPARG遗传学,可以了解代谢综合征的治疗方法.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Cell Specific Gene Expression
13.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.4K
GPCRs Regulate Adenylyl Cylase Activity
5.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165


